CytoGenix, Inc. Initiates Ferret Testing Expecting Positive Results for Avian Flu Vaccine Study

NEW BRAUNFELS, Texas--(BUSINESS WIRE)--CytoGenix, Inc. (Pink Sheets:CYGX) today announced that it has initiated the process of testing CytoGenix’s novel liner DNA technology on ferrets, with the expectations of a positive result, furthering the development of the vaccine candidate.

MORE ON THIS TOPIC